IP Verse

Formulations Of Enzalutamide

Patent No. EP3725778 (titled "Formulations Of Enzalutamide") was filed by Astellas Pharma on Sep 11, 2013. The application was issued on Aug 18, 2021.

Patent Summary

Pharmaceutical compositions of enzalutamide, an androgen receptor signaling inhibitor, that have improved solubility and absorption compared to crystalline enzalutamide. The compositions contain amorphous enzalutamide dispersed in a polymer called hydroxypropyl methylcellulose acetate succinate (HPMCAS). This polymer enhances enzalutamide concentration in solution. The amorphous enzalutamide dispersion provides higher maximum drug concentration (MDC) and area under the curve (AUC) in dissolution tests. The compositions also have rapid disintegration and dispersibility properties. The process involves preparing the amorphous enzalutamide dispersion, mixing/granulating it, and tableting.

Patent Family

Patent Family

Patent Oppositions (11)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
ACCORD HEALTHCAREMay 18, 2022TER MEER STEINMEISTER & PARTNER
ALFRED E TIEFENBACHERMay 18, 2022HAMM & WITTKOPP
BULLE DRMay 18, 2022KUTZENBERGER WOLFF & PARTNER
ELKINGTON AND FIFEMay 18, 2022ELKINGTON AND FIFE
HAMM & WITTKOPPMay 18, 2022HAMM & WITTKOPP
MAIWALDMay 18, 2022MAIWALD
STADA ARZNEIMITTELMay 18, 2022HAMM & WITTKOPP
SYNTHONMay 18, 2022HAMM & WITTKOPP
DR SCHONMay 17, 2022DR SCHON
ZENTIVA KSMay 13, 2022REDDIE & GROSE
SANDOZMay 11, 2022MAIWALD

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3725778

ASTELLAS PHARMA
Application Number
EP20177837A
Filing Date
Sep 11, 2013
Status
Granted And Under Opposition
Jul 16, 2021
Publication Date
Aug 18, 2021
External Links
Slate, Register , Google Patents